Advertisement
Home »

Selpercatinib Doubles Progression-Free Survival in RET-Mutated NSCLC

Oct 27, 2023

REFERENCES & ADDITIONAL READING

Gandhi L, et al. N Eng J Med. 2018;378:2078–2092.

 

Drilon A, et al. J Clin Oncol. 2023;41(2):385–394.

 

Ho Fung Loong H, et al. Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Abstract LBA4, ESMO 2023, 20–24 October, Madrid, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement